Development of novel nanotherapeutic pipelines to enhance cancer-specific immunity
build significant value in our nanomaterial drug candidates that address unmet medical needs
We aspire to substantially improve health care using our nanotechnology platforms
PDX Pharmaceuticals was founded in 2010 as a start-up from the Biomedical Engineering Department at OHSU. The company, in collaboration with the Knight Cancer Institute (KCI) of OHSU, has developed novel cancer therapeutics by combining our respective expertise in nanotechnology and cancer systems biology. PDX Pharma is conducting IND enabling studies of its drug candidates (AIRISE-02 and ARAC-02), both funded by the National Cancer Institute (NCI). The company is raising additional private investment to complete clinical trials by 2025.
Nanoparticle platform for co-delivering siRNA, drugs, vaccines, and/or immunotherapies. This proprietary nanoparticle can load multiple cargo types at once and is capable of targeted delivery to solid tumors upon intravenous administration. Given intratumorally, it can deliver siRNA and adjuvant to both cancer and antigen presenting cells, leading to effective in situ tumor vaccination which generates antitumor immune effects to attack cancer anywhere in the body.
AIRISE™: Intratumoral cancer nano-immunotherapy that generates antitumor immune effects to attack metastatic tumors.
ARAC™: Systemic nano-immunotherapy for deep tumors such as lung cancer. ARAC™ can render tumors sensitive to immune checkpoint inhibitors.
T-siHER2-NP™: nanoparticle based HER2-targeted therapy for HER2+ breast cancer
PDX Pharmaceuticals is a biopharmaceutical company leveraging novel nanotechnology and cancer systems biology to develop next-generation combination immunotherapies for cancer. We aspire to substantially improve health care using our nanotechnology platforms. PDX Pharma was established in 2010, supported by the Biomedical Engineering Department of Oregon Health and Science University (OHSU) School of Medicine and The Oregon Nanoscience and Microtechnologies Institute (ONAMI).
Our proprietary nanoparticle platform (Pdx-NP™) can co-deliver siRNA, chemo drugs, vaccines, and/or immunotherapies and it is capable of targeted delivery of these cargos to solid tumors upon intravenous administration. We capitalize on this platform to generate next generation combination immune therapies for cancer by co-delivering therapeutics targeting complementary cancer and immune pathways, leading to synergistic clinical benefits. Our therapeutic candidates have been shown to overcome resistance of current targeted therapies and trigger antitumor immune response in animal models.
Our strategy is to build significant value in our therapeutic candidates that address unmet medical need and have substantial commercial potential, secure intellectual property rights, and initiate early stage commercial development. We are conducting IND enabling studies of two drug candidates (AIRISE-02 and ARAC-02) funded by the National Cancer Institute (NCI) and are raising additional private investment to complete their clinical trials by 2025.
Our technologies have been developed through support from NIH (NCI, NCATS, NIDDK, NIGMS, NIEHS, NIAID), ONAMI, OHSU, PNNL, and Foundations (Prospect Creek, Wayne D. Kuni & Joan E. Kuni, Gordon Moore, Hillcrest, Women’s Health Circle of Giving).